Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611001050943
Ethics application status
Approved
Date submitted
30/09/2011
Date registered
7/10/2011
Date last updated
21/12/2011
Type of registration
Retrospectively registered
Titles & IDs
Public title
Impact of mosquito coil on malaria incidence
Query!
Scientific title
Impact of spatial repellents on malaria attack rates among male residents in Southwest Sumba District, Indonesia and its entomological correlates
Query!
Secondary ID [1]
273135
0
None
Query!
Universal Trial Number (UTN)
None
Query!
Trial acronym
SPIRIT Sumba
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Malaria
270890
0
Query!
Condition category
Condition code
Infection
279064
279064
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The study is a randomized, double-blind, placebo-controlled trial to demonstrate the impact of spatial repellents against the malaria attack rates in human population in Southwest Sumba and to prove the impact associated with the entomological correlates.
45 adult men subjects in each of the four study clusters will be recruited and enrolled as the cohort. Subjects will be asked to complete a supervised malaria radical cure (regardless of blood film status at enrolment) consisting of 40mg dihydroartemisinin- 320mg piperaquine and 15mg primaquine prior to the intervention. DHA-PP is administered based on body weight (BW) targeting a total dose of 6.4 and 51.2 mg/kg BW of dihydroartemisinin and piperaquine, respectively, given in three equally divided daily doses. Doses are rounded up to the nearest half-tablet and administered orally. Primaquine is administered 30mg daily per oral for 28 days.
Intervention:
Four adjacent clusters in two villages in Southwest Sumba have been selected on the basis of demonstrated relatively high malaria prevalence and relative abundance of a dominant species of anopheline vector. Each of the study areas (cluster) where all these adult men subjects live will be randomly assigned to receive either active repellent (i.e. 0.0097% Metofluthrin) or a placebo in a standard mosquito coil (both manufactured to burn for 12 hours) for six months. Four coils will be placed in each house, and burned for 12 hours (commencing at 6PM each evening).
Within each cluster, one of 10 randomly placed homes will be assigned to receive the opposite treatment as the community assignment to active repellent or placebo. Effects among these homes would provide some assurance of relatively uniform risk of infection and mosquito behaviours among the four sites. These embedded controls will also provide analytical leverage for discerning household- versus community-level protective effects. In other words, if placebo homes within active repellent communities enjoy substantial protection from risk, one may reasonably conclude that community coverage may be an important determinant of protective effects. Likewise, we would anticipate modest protective effects among households with active repellent in placebo communities. On the other hand, poor protection among placebo households in active repellent communities (and good protection among active coil homes in placebo communities) would point to house-specific effects and little importance of coverage in any given community.
Arm 1. 90 subjects in two cluster will be given active coils.
Arm 2. 90 subjects in two clusters will be given placebo coils.
We reason that the difference in the sporozoite attack rate between cohorts living in areas (cluster) receiving active mosquito coils should reflect the impact of that active ingredient upon real risk of infection by biting anophelines in their natural habitats.
Query!
Intervention code [1]
269475
0
Prevention
Query!
Intervention code [2]
269476
0
Treatment: Other
Query!
Intervention code [3]
269477
0
Behaviour
Query!
Comparator / control treatment
Placebo coil containing no known chemical repellent and being otherwise identical to the active coil. The coils and packaging are completely indistinguishable.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
279714
0
Malaria attacks rates among the volunteers in each intervention arm. The malaria attack in each subject will be checked weekly by performing blood smear. Subjects found malaria positive will be dropped from the study
Query!
Assessment method [1]
279714
0
Query!
Timepoint [1]
279714
0
Every week during the intervention
Query!
Primary outcome [2]
279715
0
Malaria vector abundance, human blood indices, parity rates, sporozoites rate and spatial repellent action. This entomologic parameter will be monitored by Human landing Catch (HLC), larval collection, blood meal, and resting collection.
Query!
Assessment method [2]
279715
0
Query!
Timepoint [2]
279715
0
Every 2nd week during the intervention
Query!
Secondary outcome [1]
294279
0
Malaria baseline prevalence.
The outcome was assessed by conducting mass blood screening for malaria. Malaria smear slides taken by finger prick technique were read by microscopists.
Query!
Assessment method [1]
294279
0
Query!
Timepoint [1]
294279
0
Before the enrollment
Query!
Secondary outcome [2]
294280
0
The baseline of Malaria vector abundance by location, distance and time (method: human landing capture and larval collection), human blood indices (method: resting collections/ELISA/PCR), parity rates (method: ovarian dissections), and sporozoites rate (method: ELISA/PCR).
Query!
Assessment method [2]
294280
0
Query!
Timepoint [2]
294280
0
Before the enrollment
Query!
Secondary outcome [3]
294281
0
The infections risk among the study villages, i.e. the number of microscopically confirmed cases of malaria recorded in each study village from the non-recruited cohort. The study clinic and laboratory is open to all members of the village and free treatment of confirmed malaria will be offered. Hence, it is expected that most cases of symptomatic malaria in the whole village can be captured and calculated. This PASSIVE CASE DETECTION provides a separate (less precise due to interference from chronic parasitemias and hypnozoites present before coils were deployed) of infection risk among the study villages.
Query!
Assessment method [3]
294281
0
Query!
Timepoint [3]
294281
0
At the end of study.
Query!
Eligibility
Key inclusion criteria
- Male >17 years of age
- Weight >40 kg
- G6PD normal on a qualitative screen, i.e. NADPH spot test for G6PD.
- No severe anaemia
- No significant chronic illness
- Sleeps in village >90% of nights during any given month
- No plans for extended travel during study
- Willingness to sign informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- <17 years of age or female
- Weight <40 kg
- G6PD deficient or in-determinant in a qualitative screen
- Haemoglobin of <8 mg/dL
- Sleeps outside of village >10% of nights during any given month
- Plans for travel outside of village lasting more than 2 weeks
- Unwilling to sign informed consent
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
This study initially indentify suitable study sites by employing criteria such as: villages with population over thoushands people, stable malaria prevalence and known malaria vectors. Through this criteria, we selected 4 population clusters (each consists of around 100 houses) in two adjacent villages in Southwest Sumba with two household clusters. Recruitment of subjects will be by summoning demographically eligible men, identified from census data, to the study centre. The study will again be explained to them in their own language (using a local Health Worker) and they will be asked to sign a consent form. The study site physician will conduct a routine physical examination and make a determination as to the physical fitness of the volunteer to serve as a subject of this research. None of study team members, including the people who determined if a subject was eligible for inclusion in the trial, was aware to which group the subject would be allocated. Allocation is concealed by numbered mosquitoe coil containers, and it is done by personnel not involved in the study.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The households in each cluster will be arranged sequentially and the adult men inhabitant will be listed and selected on a ballot system.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Date of first participant enrolment
Anticipated
26/09/2011
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
180
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
3876
0
Indonesia
Query!
State/province [1]
3876
0
East Nusa Tenggara
Query!
Funding & Sponsors
Funding source category [1]
269953
0
Charities/Societies/Foundations
Query!
Name [1]
269953
0
Bill and Melinda Gates Foundation (BMGF)
Query!
Address [1]
269953
0
PO Box 23350
Seattle, WA 98102
Query!
Country [1]
269953
0
United States of America
Query!
Primary sponsor type
Government body
Query!
Name
The Eijkman Institute for Molecular and Biology
Query!
Address
Jalan Diponegoro no. 69
Jakarta 10430
Query!
Country
Indonesia
Query!
Secondary sponsor category [1]
268950
0
None
Query!
Name [1]
268950
0
Query!
Address [1]
268950
0
Query!
Country [1]
268950
0
Query!
Other collaborator category [1]
252270
0
University
Query!
Name [1]
252270
0
University of Hasanudin
Query!
Address [1]
252270
0
Jalan Perintis Kemerdekaan Km 10, Makassar 90245
Query!
Country [1]
252270
0
Indonesia
Query!
Other collaborator category [2]
252271
0
Charities/Societies/Foundations
Query!
Name [2]
252271
0
Eijkman-Oxford Clinical Research Unit (EOCRU)
Query!
Address [2]
252271
0
The Eijkman Building
Jalan Diponegoro No. 69
Jakarta 10430
Query!
Country [2]
252271
0
Indonesia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
271923
0
Research Ethics Committee, Faculty of Medicine, Hasanuddin University
Query!
Ethics committee address [1]
271923
0
Jalan Perintis Kemerdekaan Km10, Makassar 90245
Query!
Ethics committee country [1]
271923
0
Indonesia
Query!
Date submitted for ethics approval [1]
271923
0
Query!
Approval date [1]
271923
0
07/09/2011
Query!
Ethics approval number [1]
271923
0
UH11080201
Query!
Summary
Brief summary
The study is a randomized, double-blind, placebo-controlled trial to demonstrate the impact of spatial repellents against the malaria attack rates in human population in Southwest Sumba and to prove that impact associated with the entomological correlates. Forty five adult men subjects in each of the four study areas will be recruited and enrolled. Subjects will be asked to complete a supervised malaria radical cure (regardless of blood film status at enrolment) consisting of dihydroartemisinin-piperaquine and primaquine prior to the intervention. They will be asked to contribute a blood film once a week to check on their malaria status during a 6 month intervention period. All subjects are resident in one of four study areas within the 2 adjacent villages in Southwest Sumba District. Each of the study areas (cluster) will be randomly assigned to be given either active or placebo coils. The team will distribute mosquito coils to each household in the study areas and ensures that each household will receive the same coil and lid the coil every night. We reason that the difference in the sporozoite attack rate between cohorts living in areas (cluster) receiving active mosquito coils should reflect the impact of that active ingredient upon real risk of infection by biting anophelines in their natural habitats.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
33218
0
Query!
Address
33218
0
Query!
Country
33218
0
Query!
Phone
33218
0
Query!
Fax
33218
0
Query!
Email
33218
0
Query!
Contact person for public queries
Name
16465
0
Puji BS Asih, BSc, PhD.
Query!
Address
16465
0
Eijkman Institute for Molecular Biology,
Jalan Diponegoro No. 69 - Jakarta 10430
Query!
Country
16465
0
Indonesia
Query!
Phone
16465
0
+62-21-3917131
Query!
Fax
16465
0
+62-21-3147982
Query!
Email
16465
0
[email protected]
Query!
Contact person for scientific queries
Name
7393
0
Din Syafruddin
Query!
Address
7393
0
Eijkman Institute for Molecular Biology,
Jalan Diponegoro No. 69 - Jakarta 10430
Query!
Country
7393
0
Indonesia
Query!
Phone
7393
0
+62-21-3917131
Query!
Fax
7393
0
+62-21-3147982
Query!
Email
7393
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF